Navigation Links
Neuralstem updates clinical trial progress
Date:5/24/2010

ROCKVILLE, Maryland, May 24, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient. The first cohort of patients received five injections of the Company's spinal cord stem cells on one side of the spinal cord. The second cohort of three patients will receive ten injections, five on each side of the cord.

About The Trial

The FDA-approved Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS has been underway since January, 2010. The trial will ultimately consist of up to 18 ALS patients, who will be examined at regular intervals post-surgery, with final review of the data to come six months after the last patient is treated.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1

Related medicine news :

1. Neuralstem Receives Approval To Commence First ALS Stem Cell Trial at Emory ALS Center
2. Sutter Health Surgical Team Sends Updates From Haiti
3. CCH Updates Briefings on Tax Provisions of Estate Tax, Tax Extender, Health Care Reform Bills
4. Sunquest Announces Major Software Updates and Enhancements
5. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
6. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to FDAImports.com, LLC
9. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
10. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
11. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... More than ... Hep B United Philadelphia, and the Prevent Cancer Foundation held an event on National ... epidemic in the city of viral hepatitis, the leading cause of liver cancer. , ...
(Date:5/31/2016)... ... 2016 , ... St. Joseph Medical Center (SJMC) announced that ... enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, to ... exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment to ...
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience ... enables unprecedented portability and convenience. , The Cube is exceptionally small—it takes up ... the Cube fits easily into any space, whether in a hospital, doctor’s office, ...
(Date:5/31/2016)... ... ... Like jewels in a crown, the multiple awards presented to Fayez Spa confirm ... day spa and one of Canada’s few accredited 5 Star Spas! , The ... spa services with hair and beauty services and has resulted in creating ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016 Aloe ... in food, cosmetics and pharmaceuticals, with global volume to ... US$ 1.6 Bn. Demand for aloe vera ... and yogurts will continue its upward momentum in 2016 ... also boost positive sentiment on aloe vera, with wide-ranging ...
(Date:5/31/2016)... Israel , May 31, 2016 ... its proprietary plant-based rhCollagen technology for tissue repair products ... Chief Scientist of Israel,s Ministry ... 12 million development project for 2016. The Chief Scientist,s grant ... year,s authorized grant, which totaled NIS 4.7 million.  ...
(Date:5/31/2016)... , May 31, 2016 ... research report with comparative analysis of Asthma therapy at ... action (MoA), route of administration (RoA) and molecule type, ... releases. It also reviews key players involved in the ... and discontinued projects. Complete report on H1 ...
Breaking Medicine Technology: